The ACC Statin Intolerance App guides clinicians through the process of managing and treating patients who report muscle symptoms while on statin therapy. Clinicians can use the app to:

• Answer questions to evaluate possible intolerance to a patient's current statin prescription.
• Follow steps to manage and treat a patient who reports muscle symptoms on a statin.
• Compare statin characteristics and drug interactions to inform management of LDL-related risk.

Search "ACC Statin Intolerance" on the web or in your app store to download today.

The information and recommendations in this app are derived from ACC/AHA's 2013 Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, and the prescribing information for each statin. It was developed as part of the American College of Cardiology's "LDL: Address the Risk" Initiative and further refined and vetted by physicians, physician assistants, nurse practitioners, pharmacists, and other relevant specialties; and through user testing in care settings with patients.

This app was developed as part of the ACC's LDL: Address the Risk Initiative.  Financial support for the LDL: Address the Risk Initiative was provided by Amgen Inc.  All of the content was independently developed with no sponsor involvement.

The Statin Intolerance App is intended to be used by clinicians at the point of care to evaluate, manage, and treat a patient who reports muscle symptoms while on a statin. Clinicians may also find some parts of the app useful at statin initiation. The App may also serve as a comprehensive resource and teaching tool for students, trainees, and any clinician less familiar with standard guidance and protocols for addressing statin intolerance.

The App contains three sections that can be used separately or in series, depending on the knowledge and needs of the clinician. The clinician can:

1. Answer questions to evaluate patient's possible intolerance to current statin prescription
2. Follow guided next steps for managing and treating a patient who reports muscle symptoms while on a statin.
3. Compare statin characteristics and drug interactions to inform management of LDL-related risk.

Yes, the app is available free to everyone both on the web and in app stores. You do not have to be an ACC member.

You can provide thoughts, feedback, and suggestions on version 1 of the Statin Intolerance App in two ways:

• Fill out the official feedback survey here. You can also access the survey under the App's "About the App" tab.
• Leave comments on the iTunes page for the App.

ACC will also collect data through analytics, usability studies and impact studies. ACC hopes to translate comments into future reorganization, refinement and enhancements to the App.

The Statin Intolerance App was developed as part of the ACC's LDL: Address the Risk Initiative. The purpose of this Initiative is to improve patient outcomes by increasing awareness of the gaps in lipid management, including the importance of managing LDL-related risks. The LDL: Address the Risk Think Tank convened in 2013 and identified perceived statin intolerance as a major barrier to statin adherence, and a topic to be addressed by the Initiative.

The Statin Intolerance App is also part of a larger and ongoing effort of the American College of Cardiology to help its members and other clinicians translate guidelines and other clinical policy statements into practice at the point of care.

The App is targeted to clinicians who care for patients with or at risk for atherosclerotic cardiovascular disease. While the app is not intended for patient use, it is freely available online and in the app stores to all users.

The information and recommendations in the App are derived from ACC/AHA's 2013 Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, and the prescribing information for each statin. Content was further refined and vetted by physicians, physician assistants, nurse practitioners, pharmacists, and other relevant specialties; and through user testing in care settings with patients. The App contains a reference section with each of the source documents, as well as supplemental resource information from ACC/AHA guidelines and other sources.

The initial concept and content for the Statin Intolerance App was developed by the LDL: Address the Risk Initiative workgroup, comprised of clinicians representing cardiology, pharmacy, nursing, and physician assistants. Design and development of the App was led by technical experts and informed by multiple rounds of user testing with similar clinical representation. Overall content and design of the App was refined and vetted by physicians, physician assistants, nurse practitioners, pharmacists, and other relevant specialists; and through user testing in care settings with patients.

The Statin Intolerance App was created with the versatility, easy dissemination, and iterative nature of the mobile platform in mind. Version 1 of the Statin Intolerance App was designed as a thorough and comprehensive tool, useful as both an actionable and educational tool. ACC hopes to use feedback gathered from the use of the current App to inform future reorganization, refinement and enhancements.

The Statin Intolerance App is an output of ACC's LDL: Address the Risk Initiative, a quality initiative aimed at improving patient outcomes by driving awareness of gaps in lipid management and the importance of managing LDL-related risk. It is also part of the ACC's growing Clinical Mobile App Collection, consisting of tools for use "on the go" to help optimize patient care. Along with the ASCVD Risk Estimator App, it is focused on helping implement recommendations from ACC/AHA's 2013 Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults at the point of care. More information about the ACC Clinical App Collection can be found here.

The Statin Intolerance App was developed solely as a product of the ACC. However, the content for the app was reviewed by more than 25 clinicians representing guideline writers, ACC committees, ACC members, and representatives from other relevant societies and organizations. While the content of the Statin Intolerance App may overlap with recommendations from other specialty societies, there may be differences or additional guidance that is not reflected in this App.

The Statin Intolerance App includes some patient demographic questions such as age, sex, race/ethnicity, and statin prescription. This information can be emailed anonymously from the app during the course of an app session to the user's personal email. However, the app does not record or store any of this information. Anonymous general user behavior (e.g., number of people who downloaded the App, how many times a day the App was used, which buttons in the app are clicked most often) will be gathered through Google Analytics.

Version 1 of the Statin Intolerance App does not currently have the capability for EHR integration. However, the ACC is actively exploring EHR integration as one way to increase the utility of our Apps in the future.

The App is available for free online at Tools.ACC.org/StatinIntolerance or for download in the iTunes or Google Play App stores. Search "ACC Statin Intolerance."

Contact the ACC at 1-800-253-4636 or resource@ACC.org.